Banzel generic
Banzel is an anti-epileptic drug owned by Eisai Inc, which was first authorized for market use on 3rd March 2011. The active ingredient in Banzel is rufinamide. Eisai Inc holds a total of 2 patents for Banzel, both of which have expired.
When will Banzel generic be available?
The generic for Banzel could potentially be released after 14th May 2023. The last patent, titled 'Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic', expired on 2023-05-14.
Banzel uses
Containing the active ingredient rufinamide, Banzel is primarily used in the treatment of epileptic seizures. rufinamide works by stabilizing electrical activity in the brain to help control seizures.
Banzel patent expiration
Banzel has a total of 2 patents, both of which have expired. The last patent, titled 'Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic', expired on 14th May 2023. Thus, the Banzel generic could potentially be released after this date. Below are the details of the patent: